Latest news with #Dalgety
NZ Herald
24-04-2025
- Sport
- NZ Herald
Carter Dalgety aims for Group 1 wins at Alexandra Park races
But while the son of trainers Cran and Chrissie Dalgety usually takes the road less travelled, tonight he will be happy to be taking the shortest way home. Dalgety will drive exceptional pacing filly Beside Me in the $100,000 Pascoes Oaks, and Republican Party in the $100,000 Dawson Harford Messenger, and the plan with both is simple: be on the markers. That looks certain with Republican Party (barrier one), who finally gets a good draw in the 2700m mobile and has options to lead - but more likely trail - either Rakero Rocket or Chase A Dream. 'It is so good to get a good draw with him because he has been going great [in] races but covering so much ground,' says Dalgety. 'In these big staying races, being on the markers is so crucial and he is going well enough to win. 'He might have had a busy summer and autumn, but he is so relaxed and cruisy in training he takes nothing out of himself, and I think that really helps.' Trailing Rakero Rocket, who in turn could make favourite Chase A Dream work, would be the ideal scenario for Republican Party. But if Chase A Dream can work to the lead and put him three back on the markers, his task becomes far more difficult - but not impossible. It probably matters a lot less what happens to Beside Me in the Oaks as she looks to be a wonderful staying filly who is perfectly suited for the step up to 2700m tonight. She showed good gate speed for catch driver Tony Herlihy last Saturday, and our most successful reinsman ever says the filly is the real deal. 'It is cool hearing Tony talk about her like that, and I'd like to go forward and lead on her,' says Dalgety. 'I don't think she has to lead to win, but being on the markers would be way better.' While Arafura is a smart front-runner having drawn the ace, she does have Without You on her back, so if she leads and gets attacked early, she would be better relenting than leading with enemies all around. Stella Rouge has looked a very, very good filly, and in any normal Oaks would be the favourite, but drawn outside Beside Me and the other favourites, she is going to need to do something special to win. Dalgety is looking at another ground-saving run with The Queens Gambit (R3, No.1) in the 2-year-old fillies races tonight but says with the Delightful Lady Final next week, he might prefer to trail Australian visitor Ripples as she heads forward at the start. Ripples was a brilliant winner of the Bathurst Gold Tiara in a 1:53.9 mile rate last start and will be the first New Zealand start for Victorian training superstar Emma Stewart. If she leads, only a failure to handle the right-handed Alexandra Park would seem a danger to her. What they said about the group 1s R5, Pascoes Northern Oaks: 'She is a really good filly, she doesn't feel like she is going fast when she is,' last Saturday's catch driver Tony Herlihy on Beside Me. R6, Breckons Trotting Derby: 'Our filly went great last week but Meant To Be has to be the one to beat on his last start win,' John Dunn on Ya Rite Darl. R7, Woodlands Northern Derby: 'He will be back to his Harness Million [winning] fitness levels this week,' Marketplace's trainer Regan Todd. R8, Fiskens Anzac Cup: 'They will run so hard how all those good horses step and where they end up will be crucial,' Oscar Bonavena's trainer Mark Purdon. R9, Dawson Harford Messenger: 'I'd love it if we could trail Rakero Rocket and he stayed in front,' Carter Dalgety on Republican Party. Herald as a 20-year-old in 1990. He became the Herald's Racing Editor in 1995 and covers the world's biggest horse racing carnivals.
Forbes
21-03-2025
- Business
- Forbes
High Yields And Higher Returns: Inside The U.K. Cannabis Industry
The U.K. cannabis sector is projected to be worth nearly $570 million by 2028. Guarded by razor wire, over 1,300 alarms, and a 24/7 ex-military security presence, Dalgety's medical cannabis manufacturing facility is intentionally hard to find (I've got the Uber receipts to prove it). The 30,000-ft U.K. site saw £10m in investment and over four years of regulatory checks before shipping its first products to patients earlier this year. Head grower Brady Green has over 15 years of experience cultivating medical cannabis. He relocated from Canada in 2023, where he was at the forefront of the industry, leading a team of 450 growers at a 13-acre facility. 'I handed him [Green] a blank piece of paper and asked him to draw the perfect cannabis facility,' Dalgety's CEO, James Leavesley, tells me when I eventually arrive. Today that sketch is a reality. The site has been specifically designed to grow cannabis under highly controlled conditions, using energy-efficient lighting, cutting-edge hydroponic systems, and strict climate control to replicate the changing seasons throughout the plant's life cycle. The temperature —and the smell— get more intense as we progress through each stage of the growth cycle. In the cultivation rooms, the temperature is controlled to the nearest 0.5 ̊C and humidity to the nearest 1%, with selective use of air pressure so precise that you can see the spike in CO2 on the monitors when we exit the room. The first company to obtain an EU-GMP license for the cultivation, manufacture and supply of a medical cannabis flower API from the U.K.'s Medicines and Healthcare Regulatory Authority (MHRA), Dalgety is currently producing enough to fulfil 4,000 prescriptions per month. By 2026, when it expands to full capacity, it aims to produce 2,600 kg of cannabis per year, with yields boldly estimated to be 82% higher than the top 1% of cultivators worldwide. 'We're looking to increase our output by five and a half times by 2026,' Leavesley says. "We're setting our sights on the future and are optimistic that the market will grow quickly.' Dalgety is the first company to obtain an EU-GMP license for the cultivation, manufacture and supply ... More of a medical cannabis flower API from the MHRA. CEO James Leavesley. Dalgety stock photography 2023. Picture by Shaun Fellows / Shine Pix Ltd The U.K. is already known as the world's biggest producer and exporter of legal cannabis for medical and scientific purposes, largely due to Jazz Pharmaceuticals (formerly GW Pharma), which has manufactured the FDA-approved cannabis-based medicines, Epidiolex and Sativex, since the 90s. Since medical cannabis was legalized in 2018, several others have seen the opportunity— and growing demand— for a domestic market. Target Healthcare now manufactures Bedrocan oils in Glasgow and the North East-based Rokshaw Laboratories was taken over by Curaleaf — the world's largest cannabis company— in 2019. Along with Germany, the U.K. has been identified as a key market in the European cannabis sector, with industry analysts at Prohibition Partners, forecasting that the market will grow from $255 million in 2024 to nearly $570 million by 2028. [In the interests of full transparency, Prohibition Partners also own a media brand I write for in the U.K.] The lack of NHS access—fewer than five patients have been able to obtain a prescription through the country's national healthcare service—has paved the way for a prospering private market, with over 40 clinics now prescribing cannabis. Exact patient numbers are hard to come by — some estimates suggest there could be as many as 60,000 — while the NHS Business Services Authority, which collects data on private prescriptions, shows over 300,000 items were prescribed between April 2023-24, more than double that of the previous 12 months. In its recent U.K. report, Cannamonitor estimates that 79% of these prescriptions are for flower, with many high in THC and almost all imported from overseas. Dalgety is getting ready to meet this demand. Five new strains have been selected for market launch in 2025, with over 100 varieties in its library. The team drew on Green's experience when choosing genetics, importing 600 cannabis cuttings from the west coast of Canada (remarkably, only one didn't survive the journey). 'We worked with partners to import tissue culture cuttings so we didn't have to start with seed trials and spend a year finding genetics,' Green explains. 'Now we're diversifying. Our next step is to introduce strains that we think people will like, but don't necessarily know to exist, because it's difficult to grow so you don't find it on the illegal markets— exotic flavor profiles. We have such a small window of what we think is possible. Cannabis has the genetic potential to express every terpene on earth." Head grower Brady Green has 15 years of experience in the Canadian market. Dalgety stock photography ... More 2023. Picture by Shaun Fellows / Shine Pix Ltd All this is going on while a Labour government refuses to budge from its hard stance on cannabis. Although the Mayor of London, Sadiq Khan, proposed decriminalization back in 2022, Prime Minister Keir Starmer has made it clear he has 'no intention' of changing drug laws or treating cannabis use as a 'low-level' crime. Even calls to widen the availability of prescriptions for children with treatment-resistant epilepsy (many of whom are still unable to access the treatment at all) were shut down by Health Minister Karen Smith in the House of Commons in January— despite her previous support while in opposition. But many feel policy change is inevitable, especially given European countries including Malta, Luxembourg, Czechia, Switzerland, the Netherlands and Germany are all moving towards regulation. A recent report by Transform Drug Policy Foundation outlines how regulating cannabis for adult non-medical use in the U.K. could generate up to £1.5 billion in annual net benefits to the Treasury. The High Returns: The Economic Benefits of UK Cannabis Legalisation, report, predicts that a mature regulated market could capture up to 80% of the current illegal cannabis market within five years while creating up to 15,500 full-time jobs across cultivation, manufacturing, retail and ancillary services. Dalgety received over 2,500 applications in 48 hours in response to an advert for a 'cannabis grower" on the job search site, Indeed. The company now takes a more considered approach to hiring, with all employees required to undergo extensive background checks by the Home Office. The point still stands. With cannabis thought to be the biggest source of daily cash flow for operators in organized crime, polling suggests that in the U.K. and the U.S., the economic argument for regulation receives the most public support. Analysts at Transform believe this argument, while secondary to public health and social justice reasons, is becoming increasingly important politically, too. 'The economic dimensions of the cannabis reform debate are undoubtedly gaining political salience, particularly as governments face growing budgetary pressures,' write co-authors Ester Kincová and Steve Rolles. 'Public support for cannabis reform, particularly for economic reasons such as disrupting illegal profits and the potential tax windfall, is growing in both the U.S. and the U.K. Legal cannabis markets are expanding globally with reforms now unfolding on every continent. This global momentum, coupled with growing public support in the UK – polls show a majority favors legislation – suggests reform is increasingly likely, if not inevitable, with economic arguments potentially decisive.'
Yahoo
08-02-2025
- Business
- Yahoo
Inside secret £10m medical cannabis factory guarded by ex-soldiers
These amazing photographs provide a glimpse inside a unique £10 million medicinal cannabis factory in the UK. The top-secret facility is heavily protected by razor wire fencing, bullet-proof glass windows, more than 150 security cameras and a highly trained team of ex-military guards. Run by Derbyshire-based firm Dalgety, the 30,000 sq ft factory produces high-grade cannabinoids for prescription medication. Growing of cannabis for medicinal use was legalised in the UK in 2018. The Midlands site is the first in the UK that holds EU GMP certification to cultivate, manufacture and sell for distribution. READ MORE: BBC's Chris Packham tells gardeners to stop using item as RSPB pulls them from sale READ MORE: Air fryer warning as owners told to avoid using popular ingredient to prevent 'damage' CEO James Leavesley said: "It's taken four-and-a-half years to actually get to a point where we're fully licensed by the MHRA (Medicines and Healthcare products Regulatory Agency) and the Home Office to cultivate, manufacture and supply medical cannabis in the UK. "Some of the feedback we have received from doctors was that the supply of imported cannabis can be unreliable and with varying quality due to a lack of transparency of the supply chain. So that means that when patients are prescribed medical cannabis they get their repeat prescriptions, often it's not available or out of stock. "If products have to be imported it can take 12 to 20 weeks just to get into the UK. The benefit of being located here in the Midlands, as soon as we finish the growing cycle we harvest and slowly dry our product then pack it. From that moment it can be within a patient's hand inside a month." The plants – which are fed around 12 times every day - are grown in a series of medical-grade laboratories which are constantly air-filtered. The team of expert growers are all issued with specially-made dark glasses due to the powerful LED lighting used to cultivate the crop. James added: 'The lighting has been bespoke-made, and we actually create artificial wind in the room to ensure there are no microclimates.' Each plant takes five months to grow over 6ft in height when they are ready to be harvested. They are then dried and cured to remove any moisture before they are trimmed by hand and their flowers separated. Head grower Brady Green, who joined the company in 2023, said: "Our crop cycle runs about five months in total. About two weeks in the crop propagation stage, about two weeks in veg, and then flowering takes about seven to twelve weeks depending on variety. From there it takes another two weeks to dry and two weeks to cure and a little bit of time to trim. "It's important to discuss medical cannabis openly and break the stigma of this plant. It's the opposite of evil and dangerous and hopefully it can provide a lot of assistance for people." Last September the company secured their second licence, giving them permission to sell their product. The company shipped its first batch of 500 prescriptions worth of medical cannabis last month.
Yahoo
07-02-2025
- Business
- Yahoo
Inside secret £10m medicinal cannabis factory - guarded by ex-soldiers
A £10 million medical cannabis facility in the Midlands, run by Derbyshire-based Dalgety, is the first in the UK with EU GMP certification to cultivate, manufacture, and distribute high-grade cannabinoids. The 30,000 sq ft site, protected by ex-military guards and 150 security cameras, ensures a consistent domestic supply of prescription cannabis, addressing shortages caused by international imports. CEO James Leavesley said their process delivers products to patients in weeks. Dalgety's first shipment, equivalent to 500 prescriptions, was sent out last month as the firm seeks to break the stigma surrounding medical cannabis.
